Skip to content
AdAdvertisement
Value Science Weekly — health economics and market access, in your inbox

Category

Oncology Research

Oncology drives a large share of new approvals and an even larger share of spending growth. This coverage follows cancer research, approvals and the access and affordability questions that follow them.

297 articles in this topic.

Articles in this category

NICE Draft Guidance Backs Capsule Sponge Tests for Oesophageal Cancer

11/16/2026

NICE Draft Guidance Backs Capsule Sponge Tests for Oesophageal Cancer

NICE draft guidance recommends Cytosponge and EndoSign to help detect oesophageal cancer and Barrett's oesophagus. The tests need no sedation and can be done outside hospital. #SyenzaNews #MarketAccess #HealthTech
Read Article →
CHMP November 2026 Recommends Seven New Medicines for Approval

11/16/2026

CHMP November 2026 Recommends Seven New Medicines for Approval

EMA's CHMP recommended seven new medicines and 11 indication extensions at its 9 to 12 November 2026 meeting, and confirmed two refusals after re-examination.
Read Article →
ACS Updates Prostate Cancer Screening Guideline for PSA Testing

11/13/2026

ACS Updates Prostate Cancer Screening Guideline for PSA Testing

"The American Cancer Society has updated its prostate cancer screening guideline, with regular PSA testing for average-risk men aged 50 to 69." #SyenzaNews #ProstateCancer
Read Article →
Enzutrix Patent Dispute Heads to Constitutional Court: Hearing Set for 23 November

11/10/2026

Enzutrix Patent Dispute Heads to Constitutional Court: Hearing Set for 23 November

The Enzutrix patent dispute goes to South Africa's Constitutional Court on 23 November 2026. UC and Astellas are pursuing damages over the generic prostate cancer drug, while Eurolab argues the patent was never validly obtained. #SyenzaNews #MarketAccess
Read Article →
Truqap prostate cancer withdrawal: AstraZeneca pulls EU bid

11/4/2026

Truqap prostate cancer withdrawal: AstraZeneca pulls EU bid

"Truqap prostate cancer withdrawal: AstraZeneca pulled its EU bid for newly diagnosed use after EMA raised benefit-risk concerns." #SyenzaNews #MarketAccess
Read Article →
KRAS G12C inhibitor divarasib outperforms approved drugs

10/28/2026

KRAS G12C inhibitor divarasib outperforms approved drugs

The KRAS G12C inhibitor divarasib improved survival versus sotorasib or adagrasib in the phase III Krascendo 1 trial. #SyenzaNews #oncology #NSCLC
Read Article →
Izalontamab brengitecan breast cancer: 59% lower risk of progression

10/27/2026

Izalontamab brengitecan breast cancer: 59% lower risk of progression

Phase 3 PANKU-Breast01 data show izalontamab brengitecan cut the risk of disease progression or death by 59% versus chemotherapy in HR-positive, HER2-negative breast cancer. #SyenzaNews #breastcancer #oncology
Read Article →
Keytruda Monotherapy Endometrial Cancer: 43% Risk Reduction

10/27/2026

Keytruda Monotherapy Endometrial Cancer: 43% Risk Reduction

Keytruda monotherapy cut the risk of progression or death by 43% against platinum chemotherapy in dMMR endometrial cancer, in the KEYNOTE-C93 Phase 3 trial. #SyenzaNews #oncology #precisionmedicine #endometrialcancer
Read Article →
JNJ-6143 prostate cancer: 75% tumor response in Phase 1 trial

10/26/2026

JNJ-6143 prostate cancer: 75% tumor response in Phase 1 trial

JNJ-6143, an investigational first-in-class oral molecule, produced a 75% tumor response rate among patients with measurable disease in a Phase 1 study. #SyenzaNews #prostatecancer #oncology
Read Article →
Claudin 18.2 antibody-drug conjugate prolongs survival in gastro-oesophageal cancer

10/26/2026

Claudin 18.2 antibody-drug conjugate prolongs survival in gastro-oesophageal cancer

Sone-Ve doubled median overall survival versus investigator's choice in third-line and later gastro-oesophageal cancer; second-line PFS missed significance.
Read Article →
Intismeran Adjuvant Melanoma Trial Cuts Recurrence Risk by 42%

10/23/2026

Intismeran Adjuvant Melanoma Trial Cuts Recurrence Risk by 42%

Merck and Moderna report a 42% reduction in recurrence or death for intismeran plus KEYTRUDA in resected stage IIB-IV melanoma, with full data at ESMO 2026. #SyenzaNews #melanoma #MarketAccess
Read Article →
Palbociclib Maintenance in HER2-Positive Breast Cancer: EMA Withdrawal

10/23/2026

Palbociclib Maintenance in HER2-Positive Breast Cancer: EMA Withdrawal

Pfizer has withdrawn its EU application for palbociclib in HER2-positive breast cancer. EMA questioned the open-label PATINA endpoint.
Read Article →

Related topics